Sign in Subscribe
Vaccines

Rare Blood Clots Linked to Johnson & Johnson's COVID-19 Vaccine Under Investigation

Strategic Insights

— 2 min read

Federal health officials have identified rare cases of blood clots associated with Johnson & Johnson's COVID-19 vaccine, similar to reports of clotting in people who received the AstraZeneca vaccine. The vaccine's use has been temporarily halted in the US while officials investigate the cases, which have resulted in one death and several severe injuries. As the investigation unfolds, officials are emphasizing the importance of vigilant medical care and reporting of any unusual symptoms following vaccination.

Key Takeaways:

  • The FDA has recommended that vaccination sites suspend the use of Johnson & Johnson's COVID-19 vaccine while the rare cases of blood clots are investigated.
  • Since the vaccine's emergency use authorization in late February, nearly 7 million people have received the shot, with six recipients developing rare blood clots afterward.
  • The rare blood clots, known as cerebral venous sinus thrombosis, were diagnosed in combination with low levels of blood platelets (thrombocytopenia) in all six cases.
  • The vaccine was administered to six women between 18 and 48, with symptoms occurring six to 13 days after vaccination, the FDA says.
  • One patient died, and one is in critical condition; the remaining four patients are receiving specialized treatment.
  • In these cases, standard treatments like anticoagulant drugs can worsen the condition, and healthcare providers are advised to avoid using heparin, as it can cause "tremendous harm or fatal outcome."
  • The Centers for Disease Control and Prevention's (CDC) outside vaccine advisory committee has planned an emergency meeting to review the cases, and the FDA will then review that analysis.
  • There have been no reports of cerebral venous sinus thrombosis in combination with low levels of blood platelets following the administration of the Pfizer and Moderna COVID-19 vaccines.
  • While there has been no clear association with the rare blood clot cases and the use of oral contraceptives, the pause was necessary to ensure the safety of the vaccine to the American public.
  • Healthcare providers are advised to be vigilant in monitoring patients for signs or symptoms that can signify a clot within one to three weeks after the J&J/Janssen vaccine.

Statistics:

  • 7 million: The number of people who have received the Johnson & Johnson COVID-19 vaccine since its emergency use authorization in late February.
  • 6: The number of patients diagnosed with rare blood clots (cerebral venous sinus thrombosis) in combination with low levels of blood platelets (thrombocytopenia).
  • 4: The number of patients receiving specialized treatment for the rare blood clot condition.
  • 1: The number of patients who have died from the rare blood clot condition.
  • 1: The number of patients in critical condition due to the rare blood clot condition.
  • 180 million: The number of doses of the Pfizer and Moderna COVID-19 vaccines administered in the US, with no reported cases of cerebral venous sinus thrombosis in combination with low levels of blood platelets.

Sources:

  • FDA: "Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine"
  • FDA: "Janssen COVID-19 Vaccine"
  • CDC: "Vaccine Advisory Committee Meeting"
  • American Medical Association: "COVID-19: What Physicians Need to Know - Webinar Series"
  • FDA: "FDA Joins Europe in Probing Rare Blood Clots after Johnson & Johnson's COVID-19 Vaccine"
  • FiercePharma: "Feds call halt to Johnson & Johnson COVID-19 vaccine rollout after 'extremely rare' blood clot cases"

Read more